ABOUT IQVIA BIOTECH

Flexibility designed for emerging biotech

The world of drug development is rapidly changing, driven by the dramatic evolution of technology and science, and now the impact of a global pandemic. As innovative biotech companies continue to fill the pipeline, IQVIA Biotech is here to help them succeed.

IQVIA Biotech delivers flexible clinical development solutions designed to help biotech and emerging biopharma companies move forward in their effort to get treatments to patients. When you partner with our clinical operations team, you gain expertise from two decades of planning and running clinical trials exclusively for biotech companies. We understand the unique challenges, hurdles, and opportunities you face. From plan development to trial design and execution, we draw on this experience to put together the right solution, and the right team, for you.

For more information, visit our website and follow us on LinkedIn and Twitter.

THOUGHT LEADERSHIP

  • While demonstrating the value of a product is important for any organization, the pressure is more acute for small and emerging biotech companies. It’s critical to convey to investors that your drug candidate has the potential to meet the unmet needs of patients today and tomorrow. Explore 3 key components to creating a compelling value story.

  • Advancements in science and technology are driving accelerated timelines and creative pathways for oncology drug development. Oncology sponsors and regulators seek new ways to efficiently move promising therapies from the clinic to approval – embracing a streamlined path that bypasses the traditional development paradigm of standalone sequential Phase I/II/III trials.

  • For biotech companies developing an immuno-oncology (IO) therapy, the complexity of oncology clinical trials takes on new dimensions. Advances in translational science, new therapeutic platforms, unique mechanisms of action, and novel trial designs are just a few of the influences shaping the dynamic IO clinical trial space. This white paper reviews the current IO landscape and considerations for biotech companies preparing for IO studies.

  • Dermatology patients are eager to participate in trials from their homes during the COVID-19 pandemic. Sponsors and investigators managing dermatology clinical trials have quickly embraced remote and virtual tools to keep patients safe and keep trials moving forward. Join our webinar and learn how to incorporate virtual approaches into the design and delivery of dermatology trials – to lower overall study risks and increase patient engagement.

  • Patients living with cancer are among the most vulnerable during the pandemic, but sponsors and researchers understand oncology drug development must continue. This paper will discuss how COVID-19 is driving change in the oncology trial landscape and how these insights may shape the future of post-pandemic clinical development. Given the unique concerns of cancer patients, the scope of the discussion will focus on outlining innovative and flexible tech-enabled approaches and operational adjustments that can improve the patient experience.

CONTACT INFORMATION

IQVIA Biotech

1700 Perimeter Park Drive

Morrisville, NC 27560

UNITED STATES

Phone: +1-910-200-1845

Contact: Daniel Halligan

FEATURED ARTICLES

  • A biologics company needed a CRO with a dedicated oncology team to manage its Phase I, multi-center study to evaluate the safety and pharmacokinetic (PK) profile of an immunotherapeutic drug in subjects with advanced solid tumors. They found a clinical trial partner with oncology experience that could support protocol design and accelerate the start-up process to meet a quick first-patient-in (FPI) milestone.

  • Learn how IQVIA Biotech helped a biotechnology company reach critical milestones as it prepared to launch an international Phase III clinical trial for its investigational ALK inhibitor in patients with non-small cell lung cancer.

  • Our RFP planning guide is a must-have for oncology sponsors. Identify key cost drivers, save time, make planning easier. IQVIA Biotech developed this guide to help emerging oncology sponsors navigate clinical outsourcing with timeline and financial considerations in mind.

  • Long-term follow-up studies can be expensive and time-consuming for investigators, sponsors and patients. Read how virtual models can improve patient retention in long-term follow-up studies, cutting the time, cost and burden for patients and investigators.

  • The global pandemic has added complexity to the already nuanced clinical development landscape, making innovation within clinical research critical to advancing human health. There are many factors that play a role in how trial adjustments are implemented. This paper will discuss how clinical trial models are evolving as sponsors rethink the traditional research paradigm and adopt patient-centric clinical technologies and approaches, including telemedicine and remote clinical monitoring.

  • COVID-19 accelerated interest in the use of virtual trials as a way to keep trials running through the pandemic. It was an unexpected shift, but it has helped many sponsors and sites see the value of virtual for clinical research and identify where and when virtual trial elements may bring permanent benefits to clinical research, even after the pandemic is over.

  • This short video explains how and why business process outsourcing (BPO) using IQVIA Technologies for site payments offers excellent ROI for sponsors and peace of mind for sites and investigators.